Does ezetimibe raise liver enzymes?
Ezetimibe, a cholesterol absorption inhibitor, has minimal impact on liver enzymes in most patients. Clinical trials and post-marketing data show it does not significantly elevate alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels when used alone. In monotherapy studies, ALT elevations above three times the upper limit of normal (ULN) occurred in less than 1% of patients, comparable to placebo.[1][2]
What happens when combined with statins?
Combination with statins like simvastatin or atorvastatin increases the risk slightly, but ezetimibe itself contributes little. In trials such as IMPROVE-IT, ALT/AST elevations >3x ULN occurred in 0.5-2% of ezetimibe/simvastatin users versus 0.4-1.5% with simvastatin alone. Discontinuation due to liver enzyme rises is rare (under 0.3%).[1][3]
Monitoring guidelines for liver enzymes
The FDA recommends baseline liver enzyme tests before starting ezetimibe, especially with statins, and periodic monitoring if risk factors exist (e.g., obesity, alcohol use). Routine testing is not required for ezetimibe monotherapy in low-risk patients. Levels typically normalize after discontinuation.[2][4]
Rare cases of liver injury
Severe hepatotoxicity is uncommon with ezetimibe. The FDA LiverTox database reports only isolated cases of elevated enzymes or mixed hepatocellular injury, often resolving without intervention. No causal link to ezetimibe alone is firmly established; most involve statin combos or comorbidities.[5]
How does it compare to statins alone?
Statins alone cause ALT/AST >3x ULN in 0.5-3% of users, driven by dose and lipophilicity. Ezetimibe adds negligible risk, making it a safer add-on for statin-intolerant patients concerned about liver effects.[1][3]
[1]: FDA Label - Zetia (ezetimibe)
[2]: Drugs.com - Ezetimibe Side Effects
[3]: NEJM - IMPROVE-IT Trial (2015)
[4]: AHA/ACC Cholesterol Guidelines (2018)
[5]: LiverTox - Ezetimibe